Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL R SAPER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Pain Medicine

NPI
1891888095
CMS profile
358295
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$34.38

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $34.38 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Lundbeck LLC $34.38 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL R SAPER

NPI 1891888095 · CMS profile ID 358295

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Pain Medicine

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $34.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lundbeck LLC $34.3811/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145965516 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $867.79 4
PY2024 $34.38 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $741,643.58 208
PY2024 Principal investigator $778,871.45 258
PY2023 Recipient $188,670.14 42
PY2023 Principal investigator $817,852.03 284
PY2022 Recipient $694.00 1
PY2022 Principal investigator $856,999.67 290
PY2021 Principal investigator $1,105,932.40 208
PY2020 Principal investigator $729,753.82 96
PY2019 Recipient $20,043.40 4
PY2019 Principal investigator $688,115.98 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

258 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,708.00 12/31/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUT
M22-418 Atogepant-Botox Combination Study No dispute reported 06/30/2026 1100765465
Principal investigator 1 ABBVIE INC. $400.00 12/31/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
M23-714 Ubrelvy Menstrual Migraine No dispute reported 06/30/2026 1100765467
Principal investigator 1 ABBVIE INC. $600.00 12/31/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
M21-201 Atogepant Ph3 EM Peds (3101-307-002) No dispute reported 06/30/2026 1100765469
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $500.00 12/31/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1130926567
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $2,054.85 12/31/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1130926865
Principal investigator 1 PFIZER INC. $203.00 12/26/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1130952029
Principal investigator 1 PFIZER INC. $3,000.00 12/26/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1130952169
Principal investigator 1 PFIZER INC. $500.00 12/26/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130952175
Principal investigator 1 H. Lundbeck A S $250.00 12/20/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1145888146
Principal investigator 1 H. Lundbeck A S $150.00 12/20/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1145888148
Principal investigator 1 ABBVIE INC. $829.05 12/19/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100761976
Principal investigator 1 ABBVIE INC. $6,150.00 12/19/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1100761984
Principal investigator 1 PFIZER INC. $750.00 12/13/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130954448
Principal investigator 1 PFIZER INC. $7,587.91 12/12/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130952181
Principal investigator 1 PFIZER INC. $500.00 12/12/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130954442
Principal investigator 1 PFIZER INC. $223.25 12/10/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1130964081
Principal investigator 1 Ipsen Innovation $255.48 12/09/2024 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1076245253
Principal investigator 1 Ipsen Innovation $126.00 12/09/2024 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1076245255
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $81.00 12/06/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241428
Principal investigator 1 ABBVIE INC. $7,132.00 12/04/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100758763
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,840.15 12/03/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241684
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,154.25 11/26/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241688
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $2,054.85 11/20/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1130925212
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,875.30 11/20/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130925220
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,881.95 11/20/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1130925224
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $266.00 11/20/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130925232
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,502.90 11/20/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130925539
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,815.45 11/20/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130925551
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,476.30 11/20/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1130926556
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,017.45 11/20/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130926869
Principal investigator 1 PFIZER INC. $1,250.00 11/14/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130952016
Principal investigator 1 PFIZER INC. $750.00 11/14/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130952022
Principal investigator 1 ABBVIE INC. $99.90 11/08/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age. No dispute reported 06/30/2026 1100754679
Principal investigator 1 ABBVIE INC. $540.50 11/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1100753609
Principal investigator 1 ABBVIE INC. $5,000.00 11/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
School Intervention Program to Promote Healthy Lifestyle Among Male Adolescent Students in King Faisal Residential City, Jeddah, Western Region, 2014-15 No dispute reported 06/30/2026 1100753611
Principal investigator 1 ABBVIE INC. $3,265.00 11/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety of Atogepant in Pediatric Subjects 6 to 17 Years of Age With Episodic Migraine No dispute reported 06/30/2026 1100753613
Principal investigator 1 ABBVIE INC. $3,315.94 11/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1100753615
Principal investigator 1 PFIZER INC. $500.00 11/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130951863
Principal investigator 1 ABBVIE INC. $1,664.55 11/06/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
School Intervention Program to Promote Healthy Lifestyle Among Male Adolescent Students in King Faisal Residential City, Jeddah, Western Region, 2014-15 No dispute reported 06/30/2026 1100752251
Principal investigator 1 ABBVIE INC. $658.80 11/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety of Atogepant in Pediatric Subjects 6 to 17 Years of Age With Episodic Migraine No dispute reported 06/30/2026 1100751669
Principal investigator 1 H. Lundbeck A S $350.00 11/01/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1145887512
Principal investigator 1 H. Lundbeck A S $175.00 11/01/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1145887514
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,633.40 10/30/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241432
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,455.40 10/30/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241690
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $49.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130921334
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,476.30 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1130925216
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,500.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130925228
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $500.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130925388
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $2,400.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130925531
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,389.85 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130925535
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $500.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130925543
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $49.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130925547
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,775.55 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1130926067
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $49.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130926070
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,500.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1130926074
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,722.35 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130926078
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $49.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130926244
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,330.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1130926249
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $500.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130926252
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $2,835.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130926559
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,500.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130926563
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $150.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130926571
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $49.00 10/22/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130926574
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $750.00 10/22/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241682
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $750.00 10/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241430
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $750.00 10/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241708
Principal investigator 1 PFIZER INC. $2,590.65 10/17/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1130986806
Principal investigator 1 PFIZER INC. $9,253.39 10/17/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130986812
Principal investigator 1 PFIZER INC. $702.50 10/17/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130987788
Principal investigator 1 PFIZER INC. $4,203.39 10/17/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130987795
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,621.65 10/15/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241686
Principal investigator 1 ABBVIE INC. $1,680.00 10/10/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100748150
Principal investigator 1 ABBVIE INC. $365.85 10/09/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100747938
Principal investigator 1 ABBVIE INC. $392.85 10/09/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100747940
Principal investigator 1 ABBVIE INC. $581.25 10/03/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100746138
Principal investigator 1 ABBVIE INC. $7,645.00 10/03/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100746140
Principal investigator 1 ABBVIE INC. $651.30 10/03/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1100746174
Principal investigator 1 PFIZER INC. $500.00 09/26/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131019011
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $2,693.25 09/21/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1130999477
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $2,872.80 09/21/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1130999489
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,502.90 09/21/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131000355
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $500.00 09/21/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1131000956
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,689.10 09/21/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131000963
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,722.35 09/21/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131000968
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,775.55 09/21/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1131001039
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $3,404.80 09/21/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1131001634
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,600.00 09/21/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1131001641
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,330.00 09/21/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1131001646
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,500.00 09/21/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1131003891
Principal investigator 1 PFIZER INC. $2,041.74 09/19/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131019017
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,615.00 09/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241414
Principal investigator 1 PFIZER INC. $1,009.33 09/12/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131020121
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,711.90 09/10/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241410
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,860.10 09/10/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241424
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,466.32 09/10/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241704
Principal investigator 1 PFIZER INC. $3,207.54 09/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131020058
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 09/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241416
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 09/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241418
Principal investigator 1 ABBVIE INC. $1,506.00 09/03/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1100739070
Principal investigator 1 ABBVIE INC. $9,547.00 09/03/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100739104
Principal investigator 1 ABBVIE INC. $2,074.58 09/03/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1100739106
Principal investigator 1 ABBVIE INC. $4,604.00 09/03/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100739108
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,466.32 09/01/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241694
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $2,872.80 08/28/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1130999483
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,815.45 08/28/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131000267
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $399.00 08/28/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131001051
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $3,404.80 08/28/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1131001838
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,722.35 08/28/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131003885
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $266.00 08/28/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131003897
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,466.32 08/27/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241702
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.70 08/19/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241412
Principal investigator 1 ABBVIE INC. $700.00 08/15/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1100736646
Principal investigator 1 PFIZER INC. $1,414.60 08/15/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131015358
Principal investigator 1 ABBVIE INC. $40.50 08/13/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100735908
Principal investigator 1 ABBVIE INC. $481.95 08/06/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100735232
Principal investigator 1 ABBVIE INC. $11,626.00 08/02/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100733672
Principal investigator 1 ABBVIE INC. $3,019.00 08/02/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100734832
Principal investigator 1 ABBVIE INC. $3,894.36 08/01/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1100732840
Principal investigator 1 ABBVIE INC. $661.50 08/01/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1100732844
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $477.90 07/30/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241426
Principal investigator 1 PFIZER INC. $500.00 07/25/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131035007
Principal investigator 1 PFIZER INC. $863.55 07/25/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1131035116
Principal investigator 1 PFIZER INC. $2,236.68 07/25/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131035121
Principal investigator 1 PFIZER INC. $7,567.42 07/25/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131035545
Principal investigator 1 PFIZER INC. $500.00 07/25/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131036507
Principal investigator 1 PFIZER INC. $261.90 07/25/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131036543
Principal investigator 1 H. Lundbeck A S $1,475.01 07/24/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1145887080
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $600.00 07/23/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131001045
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,800.00 07/23/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1131001832
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $2,693.25 07/23/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131001844
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $743.00 07/11/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241420
Principal investigator 1 H. Lundbeck A S $2,254.50 07/10/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1145886996
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 07/10/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241408
Principal investigator 1 ABBVIE INC. $13,500.00 07/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1100727950
Principal investigator 1 ABBVIE INC. $9,036.25 07/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100727954
Principal investigator 1 ABBVIE INC. $18,048.00 07/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100727960
Principal investigator 1 PFIZER INC. $10,294.55 07/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1131034996
Principal investigator 1 PFIZER INC. $500.00 07/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131035002
Principal investigator 1 PFIZER INC. $500.00 07/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131036548
Principal investigator 1 ABBVIE INC. $2,552.25 07/03/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1100725796
Principal investigator 1 ABBVIE INC. $4,041.57 07/03/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1100726460
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,840.15 07/02/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241422
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,200.00 06/29/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131064462
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,000.00 06/29/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131064469
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $10,000.00 06/29/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1131065098
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $10,000.00 06/27/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1131064456
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,000.00 06/27/2024 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1131065103
Principal investigator 1 ABBVIE INC. $745.20 06/20/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100724266
Principal investigator 1 PFIZER INC. $1,310.72 06/20/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131050477
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,095.45 06/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241404
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,154.25 06/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241406
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,466.32 06/12/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241706
Principal investigator 1 ABBVIE INC. $4,686.00 06/06/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100722854
Principal investigator 1 ABBVIE INC. $11,676.00 06/06/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100722856
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,583.65 06/06/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241396
Principal investigator 1 ABBVIE INC. $2,074.58 06/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1100721684
Principal investigator 1 H. Lundbeck A S $1,461.01 05/29/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1145886826
Principal investigator 1 ABBVIE INC. $569.70 05/23/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100719392
Principal investigator 1 ABBVIE INC. $459.00 05/23/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100719422
Principal investigator 1 PFIZER INC. $9,066.80 05/23/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1131048749
Principal investigator 1 PFIZER INC. $1,009.33 05/23/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131052858
Principal investigator 1 PFIZER INC. $1,877.58 05/23/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131054353
Principal investigator 1 PFIZER INC. $2,186.03 05/23/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131062332
Principal investigator 1 H. Lundbeck A S $420.00 05/22/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1145886796
Principal investigator 1 H. Lundbeck A S $105.00 05/22/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1145886798
Principal investigator 1 H. Lundbeck A S $1,475.01 05/22/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1145886800
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,455.40 05/14/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241400
Principal investigator 1 ABBVIE INC. $16,910.00 05/09/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100717178
Principal investigator 1 ABBVIE INC. $3,950.00 05/09/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100717580
Principal investigator 1 ABBVIE INC. $3,028.32 05/08/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1100715860
Principal investigator 1 ABBVIE INC. $661.50 05/08/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1100715862
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $202.50 05/02/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241386
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 05/02/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241388
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,820.00 05/01/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241382
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,840.15 05/01/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241384
Principal investigator 1 H. Lundbeck A S $66.96 04/24/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
EPTINEZUMAB IN PARTICIPANTS WITH EPISODIC CLUSTER HEADACHE (ALLEVIATE) No dispute reported 06/30/2026 1145886668
Principal investigator 1 H. Lundbeck A S $1,461.01 04/24/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1145886672
Principal investigator 1 Amgen Inc. $44,729.00 04/20/2024 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1096315071
Principal investigator 1 Amgen Inc. $24,075.50 04/20/2024 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study EM No dispute reported 06/30/2026 1096315507
Principal investigator 1 ABBVIE INC. $405.00 04/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1100714236
Principal investigator 1 ABBVIE INC. $9,525.00 04/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100714306
Principal investigator 1 ABBVIE INC. $199.80 04/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100714308
Principal investigator 1 ABBVIE INC. $1,503.90 04/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100714316
Principal investigator 1 PFIZER INC. $500.00 04/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131049978
Principal investigator 1 PFIZER INC. $12,810.75 04/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1131054197
Principal investigator 1 PFIZER INC. $500.00 04/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131060064
Principal investigator 1 ABBVIE INC. $1,984.50 04/17/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1100714082
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,187.25 04/16/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241402
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,154.25 04/12/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241398
Principal investigator 1 Amgen Inc. $1,227.30 04/08/2024 Non-covered Recipient Entity
MI HEAD PAIN AND NEURO INST.
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1096315075
Principal investigator 1 Amgen Inc. $522.64 04/08/2024 Non-covered Recipient Entity
MI HEAD PAIN AND NEURO INST
Phase P3 Pediatric Study EM No dispute reported 06/30/2026 1096315511
Principal investigator 1 ABBVIE INC. $20,722.00 04/04/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100710992
Principal investigator 1 ABBVIE INC. $3,028.32 04/04/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1100710994
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,583.65 04/04/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241390
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $405.00 04/04/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241392
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 04/04/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241394
Principal investigator 1 H. Lundbeck A S $333.33 04/01/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1145886472
Principal investigator 1 H. Lundbeck A S $1,500.00 04/01/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1145886474
Principal investigator 1 PFIZER INC. $1,844.23 03/27/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131049476
Principal investigator 1 PFIZER INC. $7,664.22 03/21/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1131050264
Principal investigator 1 PFIZER INC. $854.55 03/21/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131058450
Principal investigator 1 PFIZER INC. $11,483.60 03/21/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1131059392
Principal investigator 1 H. Lundbeck A S $1,330.98 03/20/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
EPTINEZUMAB IN PARTICIPANTS WITH EPISODIC CLUSTER HEADACHE (ALLEVIATE) No dispute reported 06/30/2026 1145886404
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,808.80 03/19/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241374
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,466.32 03/15/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241698
Principal investigator 1 ABBVIE INC. $1,192.88 03/14/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1100708373
Principal investigator 1 PFIZER INC. $958.03 03/14/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131061304
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 03/12/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241362
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,455.40 03/12/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241368
Principal investigator 1 ABBVIE INC. $522.45 03/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100705950
Principal investigator 1 ABBVIE INC. $2,228.00 03/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100706012
Principal investigator 1 ABBVIE INC. $229.50 03/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100706014
Principal investigator 1 ABBVIE INC. $5,206.00 03/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100706016
Principal investigator 1 ABBVIE INC. $5,891.15 03/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1100706018
Principal investigator 1 ABBVIE INC. $2,093.25 03/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1100706020
Principal investigator 1 PFIZER INC. $1,000.00 03/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131050234
Principal investigator 1 PFIZER INC. $500.00 03/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131062692
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,932.64 02/29/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241696
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,809.50 02/21/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241376
Principal investigator 1 PFIZER INC. $1,317.13 02/15/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131050141
Principal investigator 1 PFIZER INC. $2,613.73 02/15/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1131061268
Principal investigator 1 PFIZER INC. $9,900.90 02/15/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1131061675
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 02/15/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241360
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 02/15/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241710
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,680.30 02/13/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241370
Principal investigator 1 ABBVIE INC. $99.90 02/07/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100703200
Principal investigator 1 ABBVIE INC. $11,751.00 02/02/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100702810
Principal investigator 1 ABBVIE INC. $2,527.41 02/01/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1100702010
Principal investigator 1 ABBVIE INC. $515.85 01/31/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100701206
Principal investigator 1 ABBVIE INC. $5,000.00 01/31/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100701214
Principal investigator 1 PFIZER INC. $750.00 01/29/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1131060733
Principal investigator 1 PFIZER INC. $19,963.30 01/25/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1131049618
Principal investigator 1 PFIZER INC. $3,157.65 01/25/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1131055069
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,154.25 01/23/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241378
Principal investigator 1 ABBVIE INC. $5,000.00 01/22/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100700816
Principal investigator 1 ABBVIE INC. $415.80 01/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100700652
Principal investigator 1 PFIZER INC. $500.00 01/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131050558
Principal investigator 1 PFIZER INC. $500.00 01/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131053081
Principal investigator 1 PFIZER INC. $8,989.04 01/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131053304
Principal investigator 1 PFIZER INC. $2,186.03 01/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131053381
Principal investigator 1 PFIZER INC. $750.00 01/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1131061280
Principal investigator 1 PFIZER INC. $13,304.65 01/18/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1131061982
Principal investigator 1 ABBVIE INC. $908.55 01/17/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100700459
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,840.15 01/16/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241372
Principal investigator 1 H. Lundbeck A S $250.00 01/12/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1145886104
Principal investigator 1 ABBVIE INC. $10,947.25 01/10/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1100699199
Principal investigator 1 H. Lundbeck A S $150.00 01/10/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1145886088
Principal investigator 1 Amgen Inc. $12,360.67 01/09/2024 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study EM No dispute reported 06/30/2026 1096315509
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,130.35 01/09/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241366
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $607.50 01/09/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241380
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,466.32 01/08/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241700
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $202.50 01/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241364
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $202.50 01/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241712
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $202.50 01/05/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1144241714
Principal investigator 1 ABBVIE INC. $3,855.00 01/04/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1100697629
Principal investigator 1 ABBVIE INC. $75.00 01/04/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1100697631
Principal investigator 1 ABBVIE INC. $3,588.74 01/04/2024 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGIGAL INSTITUTE
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1100698003
Principal investigator 1 Amgen Inc. $37,796.32 01/04/2024 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1096315073